TPST Tempest Therapeutics, Inc.
Listings ·
Tempest reported $822,000 of stockholders' equity against Nasdaq's $2,500,000 minimum, and two director resignations leave it short of several board rules. Its 10-K already carried a going-concern warning.
Tempest sold 405,000 shares and prefunded warrants for 334,000 shares to one institutional investor at $6.25 each, for about $4.1 million net. The company's cash estimate runs only into the second quarter of 2026, and it is exploring strategic alternatives.
Nasdaq sent the company a formal notice of compliance on April 24, 2025. The 8-K does not say how the price was restored, and the lead drug's Phase 3 timeline is subject to funding.
Tempest Therapeutics will cut 21 of its 26 full-time employees as it explores strategic alternatives, with cuts effective April 30, 2025. It expects about $1.5 million in cash costs, mostly severance, and its 2024 10-K said cash of $30.3 million would last at least 12 months.
| Line | FY2025 | FY2024 |
|---|---|---|
| Net income (loss) | -$26.3 million | -$41.8 million |
| Cash from operations | -$26.8 million | -$33.0 million |
| Cash and equivalents | $7.7 million | $30.3 million |
Our latest story on this, dated May 22, 2026: "Tempest Therapeutics gets Nasdaq notice on stockholders' equity, flags board independence gap". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 12, 2025: "Tempest Therapeutics prices $6.25 registered direct offering, expects $4.1 million net". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 22, 2026: "Tempest Therapeutics gets Nasdaq notice on stockholders' equity, flags board independence gap". The story links the filing or release it is based on. Read the story.
Tempest Therapeutics, Inc. trades under the ticker TPST on NASDAQ.
Tempest Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Tempest Therapeutics, Inc. is 1544227. Its filings are on SEC EDGAR.
14,806,997 shares as of 2026-05-08, per the cover page of its 10-Q filed 2026-05-14.
Our directory records Tempest Therapeutics, Inc. under United States.
Our directory classifies Tempest Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Tempest Therapeutics, Inc. is US87978U2078.
aibio.space lists Tempest Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Tempest Therapeutics, Inc. reported a net loss of $26.3 million for the fiscal year ended Dec 31, 2025, and used $26.8 million of cash in operations, per its annual report to the SEC.
$779,000 in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Tempest Therapeutics, dated May 22, 2026: "Tempest Therapeutics gets Nasdaq notice on stockholders' equity, flags board independence gap". Tempest reported $822,000 of stockholders' equity against Nasdaq's $2,500,000 minimum, and two director resignations leave it short of several board rules. Its 10-K already carried a going-concern warning. Source.
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,5.01,5.02,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,7.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 1.01,3.03,5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio